The effect of amikacin in the prevention of ventilator-induced pneumonia
Phase 3
Recruiting
- Conditions
- Pneumonia.Ventilator associated pneumoniaJ95.851
- Registration Number
- IRCT20220702055337N1
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 126
Inclusion Criteria
Age 18 and above
Absence of lung disease and lung mass
No use of chemotherapy drugs
Absence of intestinal nutrition
No receiving of Antibiotics before the onset of VAP
Absence of kidney disease and chronic kidney failure with basic glomerular filtration less than 30 ml in minutes
No removing the patient's tracheal tube within the next 48 hours after insertion
Lack of sensitivity to amikacin
Absence of Myasthenia gravis
Not pregnant or Lactating
Absence of covid-19 disease (negative PCR)
GFR more than 50
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Early and late onset pneumonia. Timepoint: 14 days from beginning. Method of measurement: CPIS checklist.;Mortality. Timepoint: 14 days. Method of measurement: Checklist.;Ventilator time. Timepoint: 14 days. Method of measurement: Checklist.;ICU hospitalisation. Timepoint: 14 days. Method of measurement: Checklist.;Glomerular filtration rate. Timepoint: Every day for 14 days. Method of measurement: GFR formula.
- Secondary Outcome Measures
Name Time Method